Embryonic stem (ES) cells hold great promise for treating degenerative diseases, including diabetes, Parkinson's, Alzheimer's, neural degeneration, and cardiomyopathies. This research is controversial to some because producing ES cells requires destroying embryos, which generally means human embryos. However, some of the surplus human embryos available from in vitro fertilization (IVF) clinics may have a high rate of genetic errors and therefore would be unsuitable for ES cell research. Although gross chromosome errors can readily be detected in ES cells, other anomalies such as mitochondrial DNA defects may have gone unrecognized. An insurmountable problem is that there are no human ES cells derived from in vivo-produced embryos to provide normal comparative data. In contrast, some monkey ES cell lines have been produced using in vivo-generated, normal embryos obtained from fertile animals; these can represent a "gold standard" for primate ES cells. In this review, we argue a need for strong research programs using rhesus monkey ES cells, conducted in parallel with studies on human ES and adult stem cells, to derive the maximum information about the biology of normal stem cells and to produce technical protocols for their directed differentiation into safe and functional replacement cells, tissues, and organs. In contrast, ES cell research using only human cell lines is likely to be incomplete, which could hinder research progress, and delay or diminish the effective application of ES cell technology to the treatment of human diseases.
INTRODUCTION T
HE ULTIMATE GOAL of stem cell technology is to direct cultured, undifferentiated cells into forming functional cells, organs, and tissues for replacement therapies (Rippon and Bishop, 2004) . For this purpose, it is essential that in vitro-derived materials remain stable after transplantation, that is, they will not revert into or contain less differentiated, possibly cancerous cells, and that their specific functions are maintained. Therefore, cell lines used for experimental studies or for therapeutic purposes should be selected for genetic stability and "normality," as far as these properties can be established and maintained. Before beginning therapeutic applications to humans, it could be important to examine the safety and efficacy of stem cell-based therapies by transplantation studies in a suitable experimental, clinically relevant animal model. Nonhuman primates are ideal for such studies, but they are expensive to use and most investigators do not have access to them. However, these difficulties could be overcome if facilities with nonhuman primates would produce stem cells and distribute them in a collaborative way, which the Oregon National Primate Research Center is already doing.
There are several types of stem cells that could be used for replacement therapies. Primarily, these comprise adult stem (AS) cells and embryonic stem (ES) cells. Adult stem cells hold considerable promise for treating a wide variety of human disease conditions, and offer the advantage of being non-controversial in terms of their sources (i.e., no embryos are destroyed to produce them). Because of this, some people have suggested that AS cells can produce all of the cell types required for therapeutic applications, so there is no need to destroy embryos for generation of ES cells. So why not use human AS cells instead of ES cells in research? According to the U.S. National Institutes of Health, "Human embryonic stem cells are thought to have much greater developmental potential than adult stem cells. This means that embryonic stem cells may be pluripotent-that is, able to give rise to cells found in all tissues of the embryo except for germ cells rather than being merely multipotent-restricted to specific subpopulations of cell types, as adult stem cells are thought to be" (excerpt from NIH website on stem cells: Ͻhttp://stemcells.nih.gov/info/faqs.asp#ownsϾ). [Note that it now seems that ES cells can also generate primordial germ cells, which then go on to form gametes (Surani et al., 2004) .] However, at present we do not have sufficient information to justify using only AS cells or ES cells for research. It would be tragic, for example, to focus exclusively on AS cells, only to discover years later that they are limited in their developmental or functional competence, and then have to start over with ES cell research. That is why we believe that it is prudent to pursue research with both ES and AS cells, in complementary and parallel research studies. Ultimately, it should be possible to dedifferentiate or reprogram somatic or adult stem cells into ES cells in vitro, without using oocytes (Fig. 1 ), but this goal seems far off. Until then, the issue of where to focus research resources should be addressed.
The topic of research with ES cells fuels huge controversy, in the United States and elsewhere, because the debate is all about human ES cells. It is generally believed that, for ES cell research to advance, human embryos must be destroyed, and this is anathema to many people. Support for using human embryos to produce new ES cell lines varies widely among different countries. In England, the HFEA has approved the generation of BAVISTER ET AL. 2
FIG. 1. (A)
Transformation of a fertilized oocyte into specific tissues and organs for transplantation, using tissue culture technology (within rectangular boxes). (B) Transformation of a patient's somatic cells into ES cells and then into tissues and organs, using oocytes to perform nuclear reprogramming (SCNT) (Hwang et al., 2004) . (C) Transformation of a somatic cell into ES cells without using oocytes; this ultimate goal has not yet been reported.
human ES cell lines from surplus in vitro fertilization (IVF) embryos, and this is clearly happening elsewhere as well (e.g., in Spain and Switzerland). In South Korea, approval was given for human embryos to be produced for the express purpose of making ES cell lines, using somatic cell nuclear transfer (SCNT) (Hwang et al., 2004) . In contrast to these enlightened views, some other countries, including the United States, have banned government funding of new ES cell line production from surplus IVF embryos (Walters, 2004) , even though recent research has made this imperative (Martin et al., 2005) . We think this controversy about destroying human embryos could be defused or minimized by focusing more attention on the use of non-human primate ES cells. These cells have several advantages over human ES cells that are discussed below, and we believe that research progress could be improved by augmenting human ES cell research with studies using non-human primates. Because of this, now is the time to study non-human primate ES cell lines, in order to gain important information about ES cell characteristics that will facilitate the process of deriving cells, tissues, and organs suitable for transplantation Lester et al., 2004) . This research must include development of better culture systems that maintain ES cells in their undifferentiated, pluripotent state and that preserve karyotypic stability and basic cell properties such as mitochondrial functions. In addition, culture systems need to support the differentiation of ES cells into very large, physiologically normal populations of desirable phenotypes that are suitable for clinical applications.
WHERE DO EMBRYONIC STEM CELLS COME FROM?
ES cells are derived from pre-implantation blastocysts, which develop from fertilized oocytes. This raises two important concerns: any oocyte defects will most likely be inherited by ES cells, and large numbers of oocytes will be needed for reprogramming somatic cells into ES cells (Fig. 1) . The blastocyst is the first stage of preimplantation development that exhibits distinctly separate cell lineages (Rossant, 2001) . These lineages are the trophectoderm, which progresses to form placental structures, and the inner cell mass (ICM), which contains pluripotent cells that form all the fetal tissues. These ICM cells are the progenitors of ES cells. Any genetic defects in the oocyte will likely be replicated or even enhanced in the ES cells derived from them. The most common cause of chromosomal errors is non-disjunction during meiosis, resulting in aneuploidy (Hassold and Hunt, 2001; Munne et al., 2002) , and this defect is irreparable. Aneuploidy occurs at a high frequency in human IVF embryos. In addition, mitochondrial DNA (mtDNA) defects occur in oocytes of infertile patients and their frequency appears to increase with age (Keefe et al., 1995) , indicating that such defects would persist in ES cells rather than be eliminated. Therefore, to obtain normal stem cells capable of developing into functional organs and tissues, it is essential to start with oocytes that are free of DNA anomalies. This is a significant problem for producing normal human ES cells, as discussed below. Several monkey ES cell lines have been produced and used in differentiation studies Lester et al., 2004) (Table 1) . Monkey ES cells have also been derived from parthenogenetically activated eggs that developed to the blastocyst stage (Vrana et al., 2003) . Parthenogenesis is the process by which an egg can develop without the presence of the male genome. Using this approach, primate ES cells that appear morphologically normal can be derived without the need to create or destroy a viable embryo. Although this may assuage ethical concerns about destroying human embryos, such ES cell lines are genetically abnormal, and there is a high probability of irreparable imprinting errors (Vrana et al., 2003) .
WHY DO WE NEED TO STUDY PRIMATE ES CELL LINES?
Although much basic research has been done with mouse ES cells, it is now clear that they are not faithful models for primate (human and monkey) ES cells. "They are different in cell/colony morphology, growth requirements and molecular signatures defining various developmental stages. For example, LIF (leukocyte inhibitory factor) . . . is able to sustain undifferentiated murine but not primate ES cell growth" . Development of improved culture methods for primate ES cells is critically important, but the different responses of mouse ES cells to chemical factors in the medium make it impractical to apply methods developed for them to primates, or vice-versa. Several molecular markers that are specific to ES cells are found only in primates (e.g., SSEA-3, SSEA-4, TRA-I-60), while others are specific to mice (e.g., SSEA-1) (Henderson et al., 2002) . Thus, fundamental differences between mouse and primate ES cell characteristics and properties restrict our ability to extrapolate biological and technological knowledge from the former to the latter.
WHY NOT FOCUS EXCLUSIVELY ON HUMAN ES CELL LINES?
According to the NIH Stem Cell Registry (Ͻhttp://stemcells.nih.gov/research/registry/Ͼ), there are presently 26 available human ES cell lines that may be studied using U.S. federal research funds. Although these cell lines have potential for providing data, they may have inherent problems that can restrict or even distort the collection of information relevant to transplantation therapies, as described below. Over a hundred other ES cell lines have been created worldwide since the August, 2001, U.S. government cutoff, but none of these can be studied using U.S. federal research funds. The governments of several other countries now support the production of new human ES cell lines that will not suffer from some of the inherent problems in the U.S.-approved cell lines (i.e., avoiding use of mouse feeder cells and blood serum). As a result of this dichotomy, the U.S. research effort in ES cell technology is in danger of lagging behind that in other parts of the world, and this will become more evident with time.
Most or all of the NIH-approved human ES cell lines are derived from surplus in vitro-produced (IVP) embryos made in infertility clinics; that is, the oocytes were fertilized and cultured in artificial media. Some of these oocytes may have had a high frequency of genetic errors, most commonly aneuploidies, especially if they were obtained from older infertile women (Keefe et al., 1995; Brenner et al., 1998; Barritt et al., 1999; Munne et al., 2002 Munne et al., , 2004 Daphnis et al., 2005) . To be sure, any ES cell lines derived from aneuploid or mosaic embryos can be eliminated after karyotyping them, and all of the human ES cell lines currently available for U.S. federally supported research exhibit a normal (46XX or 46XY) karyotype, according to the NIH Stem Cell Registry (Ͻhttp://stemcells.nih.gov/research/registry/Ͼ). Most of the available rhesus monkey ES cell lines also have a normal karyotype (Table 1) . However, there may be other, more subtle genetic errors, including mtDNA defects in ES cells that reduce their suitability for research and/or transplantation studies. While there are few data on human BAVISTER ET AL. 4 Pau and Wolf, 2004.) embryos, for obvious reasons, animal studies show convincingly that gene expression is frequently aberrant in IVP embryos (Ho et al., 1995; Doherty et al., 2000; Niemann and Wrenzycki, 2000; Wrenzycki et al., 2001; Rinaudo and Schultz, 2004) . Genetic and functional defects are likely to affect the ICM more than trophoblast (Bavister, 2004) . Storage of IVP embryos using cryopreservation further decreases their viability (Hasler, 1998) . Moreover, a high frequency of genetically abnormal embryos reduces the amount of viable material available for generating useful ES cell lines. In principle, such defects could also occur in non-human primate embryos, but the probability is lower than for humans because oocytes are generally obtained from young, fertile animals.
CULTURE-INDUCED PROBLEMS IN STEM CELLS
Maintaining ES cells in the undifferentiated state with a stable karyotype is challenging, and the present lack of optimal culture conditions aggravates this problem. Factors such as subcloning, cryopreservation, or exposure to proteases and defective ATP production by mitochondria could allow chromosome instability to creep into a cell line, rendering it unsuitable for further study on normal tissue derivation. It is important to periodically re-examine the karyotype stability of ES cell lines during many passages (Amit et al., 2000 (Amit et al., , 2003 . This analysis should be done about every ten passages, using conventional staining techniques, or with FISH, which has the advantage that interphase nuclei can be examined, avoiding the need to synchronize cells into metaphase (Daphnis et al., 2005) . Chromosome FISH painting probes are preferable because they can reveal translocations. Some human ES cells do not retain a normal chromosomal karyotype after culture for extended periods (Draper et al., 2004a) . Three independent human ES cell lines were revealed to be aneuploid during culture, showing distinctive chromosomal abnormalities such as translocations including the gain of chromosome 17q, and the presence of one or more isochromosomes 12p (Draper et. al., 2004b) . In these studies, on five independent occasions, an additional copy of chromosome 12 was found in cultured ES cells. Recently, chromosome 12 trisomy, as well as other changes in chromosome 2, were detected by FISH analysis in all of 17 new human ES cell lines that were initially euploid (Cowan et al., 2004) . This implies that increased dosage of genes on chromosomes 17q and 12 provides a selective advantage for the propagation of undifferentiated human ES cells. Since genetic instability is the hallmark of human cancers, the use of aneuploid ES cells could be detrimental or even dangerous in cell-based therapeutic applications.
Karyotypic instability can result from telomere shortening during senescence of human cells in culture. Eventually, the cells enter "crisis," comprising increased chromosome fusion, aneuploidy and cell death (Mathieu et al., 2004) . The different length of telomeres in germ cells and somatic cells is well documented (Schaetzlein et al., 2004) . It was recently shown that early mammalian embryos have a telomerase-dependent genetic program that elongates telomeres to a defined length (Schaetzlein et al., 2004) . This could ensure sufficient telomere reserves for maintaining chromosome integrity. The telomere elongation program is initiated during the morula-blastocyst transition and restores telomere length to a specific set point. In human embryos, telomeric fusions and translocations are associated with chromosomal instability (Lo et al., 2002) . Human AS cell lines exhibited shorter telomeres after 30 passages and are prone to karyotypic instabilities and chromosomal translocations (Pochampally et al., 2004) , which may account for late graft failure in hematopoietic stem cell transplantation (Lewis et al., 2004) . Quite possibly, some primate ES cell lines with high passage numbers may exhibit changes in telomere length and function as well as increased chromosomal abnormalities. Accordingly, telomere length analysis should also be included in the panel of tests applied to ES cell lines used for tissue derivation research (Amit et al., 2000) .
Added to uncertainties about the normality of primate ES cells is the problem of the feeder cell layers used to support them, commonly consisting of mouse embryonic fibroblasts. While these feeder cells are helpful in maintaining ES cell status, their use introduces potential problems. Mice usually have endemic viruses, so viral DNA from mouse feeder cells could possibly transfect the genome of co-cultured primate ES cells, altering their genetic characteristics and thus their usefulness for research and for transplantation. In addition, new research indicates that all of the human ES cell lines available for U.S. federally funded research share a previously unrecognized trait that fosters rejection by the immune system. Most mammalian cells exhibit N-glycolyl-neuraminic acid, or Neu5Gc, surface molecules but human cells instead express N-acetyl neuraminic acid, or Neu5Ac, which differs by a single oxygen atom (Bardor et al., 2004) . This subtle difference is apparently enough to trigger an immune response against cells exhibiting Neu5Gc. Now, recent reports indicate that human ES cells grown on mouse feeder cells take up mouse Neu5Gc molecules and then display them on their own cell membranes (Martin et al., 2005) . The vast majority of people have antibodies against this molecule. When human blood serum was added to the mouse feeder cell-cultivated human ES cells in vitro, they were attacked and killed by antibodies. This indicates that, if these human ES cells or derivatives were implanted in a human, they would provoke an immune rejection response. This finding essentially mandates the production of new primate ES cell lines that have never been exposed to mouse feeder cells. Moreover, most culture media used for ES cells contain serum, usually from cattle, which opens up the possibility of infection with pathogenic organisms, including viruses, and prions thought to be responsible for encephalopathies such as Creutzfeldt-Jakob Disease (Bird, 2004) . Culture medium containing serum caused mitochondrial defects in sheep and bovine embryos (Shamsuddin and RodriguezMartinez, 1994; Dorland et al., 1995) .
These scenarios could make primate ES cells grown in such culture systems suboptimal for research, and certainly unusable for clinical transplantation therapies. There is considerable concern about safety issues related to clinical applications of ES cells (Dawson et al., 2003) . Therefore, it is necessary to develop culture systems for ES cells that avoid use of mouse feeder cells and serum, and to use them to produce new cell lines for research and clinical applications. One helpful approach is to use human instead of mouse feeder cells (Richards et al., 2002; Cheng et al., 2003; Hovatta et al., 2003; Amit et al., 2003) . Alternatively, several studies have shown that human ES cells can be grown without using any feeder cells or serum (Carpenter et al., 2004; Rosler et al., 2004; Amit et al., 2004) . However, only by starting with fresh ES cells that were never exposed to mouse feeder cells or serum can we eliminate the possibility of infection from these sources.
Heterogeneity of stem cell cultures is another (Conley et al., 2004) . Obviously, we need to study stem cells that are genetically normal, functional and competent to differentiate into useful tissues and organs for transplantation. But because of the need to repeatedly passage stem cells, these desirable characteristics may deteriorate with increasing passage number. This contraindicates studies on cell lines with very high passage numbers, for example, Ͼ30, because their characteristics may be representative of dysfunction and imminent cell death. Studies showing that chromosomal anomalies are correlated with increasing passage number, as discussed above, amply support this caveat.
WHAT ARE THE PROPERTIES OF "NORMAL" EMBRYONIC STEM CELLS?
There is another, critically important reason why progress in deriving cells, tissues and organs from human ES cell lines is likely to be hindered and why research done exclusively with these cells may provide anomalous data without us knowing: there are no normal, in vivo-produced human embryos with which to make ES cell lines that can be used for comparison with those derived from IVP embryos. For practical and ethical reasons, it is doubtful if in vivo-produced human embryos will ever be available for in vitro experiments. Thus, we have no way of knowing for certain which human ES cell lines are normal and which are defective.
While many of the available human ES cell lines are said to be "pluripotent," the evidence for this mostly consists of injecting cells into immunodeficient mice and showing that they can develop into various tissues characteristic of the three primary germ layers. This is not adequate to demonstrate "pluripotency," in the sense that ES cells can produce all of the fetal organs and tissues. It may not be necessary to demonstrate pluripotency in every ES cell line, and indeed pluripotency may not be essential for deriving specific tissues or organs. However, a demonstrably pluripotent primate ES cell line could provide invaluable comparative information about markers that can discriminate among different cell lineages, and on the differentiation competence of various cell lines. Incontrovertible proof of pluripotency would come from producing an entire baby from ES cells, which may be feasible in monkeys though not in humans for ethical reasons.
SUPPLIES OF HUMAN OOCYTES
In order to realize the goal of using ES cells to generate cells, organs and tissues for therapeutic replacement, it will first be necessary to transform somatic cells taken from a patient into ES cells. Using the patient's own cells to supply the DNA will avoid transplant rejection problems. However, for the foreseeable future, the only way to achieve this somatic-ES cell transformation is by SCNT, which requires oocytes. Because SCNT is very inefficient, very large numbers of oocytes are needed to make even one ES cell line (Hwang et al., 2004) . Unfortunately, the supply of human oocytes is far too small to support large-scale operations of this kind, which poses a major dilemma for therapeutic applications of ES cell technology. Few infertile patients will allow significant numbers of their oocytes to be diverted to ES cell technology, and even if the donor is personally involved (i.e., she or her spouse or relative needs the ES cell technology to cure disease), the numbers of oocytes harvested from one ovarian stimulation cycle is small, about 20. Using paid oocyte donors is another possibility, as in the Korean study (Hwang et al., 2004) , but even this approach will not provide sufficient oocytes for large-scale use. Two approaches to resolve this dilemma are (i) make SCNT vastly more efficient, so that many fewer oocytes are needed, or (ii) avoid using oocytes altogether by finding ways to transform somatic cells into ES cells using culture technology. The first approach will require huge investments of time and money, and will still be objectionable on ethical grounds, and in the United States would require private funding. The second approach is no less daunting but would eliminate the moral controversy completely, and could be supported with U.S. federal funding.
HOW CAN NON-HUMAN PRIMATE EMBRYONIC STEM CELLS HELP?
Non-human primate ES cells suffer from some of the same problems described for human ES cells. However, they provide an invaluable transitional model that offers some practical and ethical advantages for ES cell research, complementing studies with human ES cells. Non-human primates such as rhesus monkeys are genetically very similar to humans, sharing Ͼ90% DNA homology (Clark et al., 2003) , and have long been used as models for studies on human diseases, behavior, reproductive biology and embryology. A major advantage for ES cell research is that some rhesus monkey ES cells have been made from in vivo-produced, presumptively normal blastocysts ( Table 1 ), so that we have a relative "gold standard" with these cells for evaluating characteristics of both monkey and human ES cells derived from IVP embryos. Second, IVP monkey embryos are usually made with gametes from young, fertile animals so that there is a lower probability of genetic defects than in surplus human embryos from IVF clinics. Third, new nonhuman primate ES cell lines can be made using U.S. federal funds, avoiding a major political obstacle with human ES cells in this country. Lastly, the safety and efficacy of transplanted cells, tissues or organs could be evaluated in non-human primates to assess the risks involved prior to human clinical studies.These facts together constitute a powerful case for the parallel development of ES cell technology in non-human primates and in humans, with the former providing critically important supportive data for eventual clinical applications of ES cell technology. This combined effort would accelerate the pace of ES cell research and its clinical applications.
A drawback to using non-human primates is that there are few naturally occurring diseases in these animals that could be treated by application of stem cell-derived tissue or organ transplants. Exceptions are monkeys with inherent neurological diseases such as Krabbé disease (Suzuki, 2003) and Parkinson's disease. The latter affliction was ameliorated by transplanting dopaminergic neurons grown from monkey ES cells into the brains of animals exhibiting this condition (Takagi et al., 2005) . However, another common disease, diabetes, can be experimentally induced in monkeys (Tal et al., 2004) . This condition was successfully reversed using allogeneic pancreatic islet transplants (Thomas et al., 2001) , suggesting that this approach could be valuable for assessing the efficacy of stem cell-derived pancreatic islet ␤-cells (Lester et al., 2004) .
WHAT NEEDS TO BE DONE WITH NON-HUMAN PRIMATE EMBRYONIC STEM CELL LINES?
At present, 18 rhesus monkey ES cell lines have been produced  Table 1 ). Ten of these lines (ORMES) were derived from IVP blastocysts at the Oregon National Primate Research Center. The remaining eight cell lines (R series) were made by James Thomson at the Wisconsin National Primate Research Center from in vivo-produced blastocysts flushed from the uteri of female monkeys after artificial insemination. A well-formed blastocyst can be collected by uterine flushing in one-third of rhesus monkey menstrual cycles (Wolfgang et al., 2001) , the same frequency as the incidence of viable pregnancies after mating or artificial insemination; thus, these flushed blastocysts are the same ones that would have produced offspring if they had not been collected. Therefore, the R series ES cells derived from these embryos represent the most normal primate (monkey or human) cell lines available.
All of the "in vivo" monkey ES cell lines (R series) possessed a normal chromosome complement (42XX or 42XY) at the time they were isolated (Table 1) . Six of the "in vitro"-derived ES cell lines have been karyotyped, and while all of them show a normal number of chromosomes, one cell line (ORMES 1) contains a balanced chromosome translocation. This anomaly emphasizes the importance of looking for more than just the correct chromosome number. Interestingly, the ORMES 1 cell line was also capable of differentiating into neuronal precursor cells, showing that partial differentiation of ES cells (Kuo et al., 2003) is not an adequate indicator of normality. All of the "in vivo" monkey ES cell lines have formed teratomas in mice, though this is not adequate proof of pluripotency, as discussed above. Most of the ES cell lines in both series are also capable of differentiating into embryoid bodies and into neuronal precursor cells (Table 1) . As stated by Pau and Wolf (2004) : "The extent of diversity among primate ES cell lines is currently unknown." "It is prudent for investigators to characterize several lines before transplantation efforts begin. The quality of ES cells among different cell lines, especially the ability to selfrenew and differentiate into a desired lineage, must be ascertained, at least by in vitro assessment, before selection for transplantation studies." These caveats apply equally well to human ES cell lines. Before embarking on extensive studies with these monkey ES cell lines, in order to improve cell culture methods and to direct differentiation into specific phenotypes, some basic information must be obtained. The key question is: what measurable characteristics could be used to select normal cells for further, in-depth studies? Such information is likely to be also applicable to human ES cells. We and others agree that a panel of cellular and molecular tests should be applied to primate ES cells to ascertain their identity and functional competence (Brivanlou et al., 2003) . The question of functional competence of ES cells is critically important, and genetic and molecular characterizations need to be placed in context with this. Several key criteria for evaluating ES cells have been suggested, but we believe that these should include mitochondrial characteristics because of the importance of these organelles for normal cell functions, in both preimplantation embryos and somatic cells. Since the possible role of mitochondria in stem cell research has not been widely addressed, we will discuss it in some detail here.
Why do we think that mitochondria are important for ES cell studies? a. Mitochondrial localization. Mitochondria play a key role in early development, though one that is not fully understood (Leese, 1991; Brison and Leese, 1994; van Blerkom et al., 2000; Bavister and Squirrell, 2000; Ludwig et al., 2001 ). Mitochondrial structure and activity change strikingly during preimplantation development, suggesting an increasingly important role once differentiation (blastocyst formation) occurs. Most strikingly, during fertilization in hamsters and rhesus monkeys, active mitochondria cluster around the pronuclei, while in hamsters this mitochondrial distribution persists into embryo cleavage stages Squirrell et al., 2003) . Some somatic cells, such as fibroblasts and neurons, also exhibit pronounced clustering of active mitochondria (Yaffe, 1999; Mattson and Partin, 1999) . The cytoskeleton is responsible for organizing mitochondria into a non-random distribution, and the mitochondrial distribution profile is critically important for cell functions. While the precise reasons for this clustering and its function are unknown, it may aid in the transfer of nuclear-encoded polypeptides that must be imported into mitochondria, or in facilitating the action of mitochondrial transcription factors such as TFAM. In some cells, the distribution of mitochondria is under genetic control (Yaffe, 1999) . In fibroblasts, mitochondria cluster around the nucleus while peripheral cytoplasm is devoid of mitochondria, exactly the same profile as in fertilizing oocytes and early preimplantation embryos (Yaffe, 1999; . In neurons, clustering of mitochondria is involved in establishing cell polarity and disrupting their distribution results in loss of polarity (Mattson and Partin, 1999) . In view of these observations on preimplantation embryos and on somatic cells, it seems likely that clustering (non-random distribution) of mitochondria occurs in ES cells and thus may be important for their normal functions. If so, the mitochondrial distribution profile(s) could become a simple marker of ES cell competence that is easily assessed using fluorescent staining and confocal microscopy, as well as an indicator of impending differentiation. However, this remains to be examined.
b. ATP production. By analogy with their fundamental metabolic roles in somatic cells (Mattson and Partin, 1999; Yaffe, 1999) , we can expect that mitochondria have similar importance in the ES cells, which are primordial somatic cells. Energy for embryo development through the cleavage stages is obtained primarily by oxidative phosphorylation (i.e., via mitochondrial pathways), probably utilizing oxidizable amino acids such as glutamine. Once differentiation begins (blastocyst development), glycolysis increases (Leese, 1991; , but oxidative phosphorylation is still important in the blastocysts of most species (Brison and Leese, 1994) . Culture conditions that affect mitochondrial activity, such as providing oxidizable substrates, during oocyte maturation or early cleavage stages can profoundly alter embryo development (Zheng et al., 2001a (Zheng et al., , b, 2002 Rose-Hellekant et al., 1998; McKiernan et al., 1991; Krisher and Bavister, 1999) , while "uncoupling" mitochondria caused apoptotic cell death in embryos (Liu et al., 2001) . In view of the importance of mitochondrial ATP production by the time of blastocyst formation, we can expect that in ES cells oxidative phosphorylation (mitochondrial activity) provides most of the energy for cell functions and is therefore essential for stability and functional competence. Genetically defective mitochondria may be manifested as abnormal performance of ES cells. The mitochondria may be deficient in ATP production, and/or exhibit anomalous localization during the cell cycle that precludes viability. Because of the consequences for understanding the importance of mitochondria for ES cell function and competence, potential linkages among morphological, metabolic and genetic parameters should be examined.
c. mtDNA defects and copy number. Two key questions that need to be addressed are: do mitochondrial DNA mutations accumulate in ES cells? If so, do they affect ES cell quality and functional capacity? Mitochondria are not only the major site of ATP production in cells but also an important source of reactive oxygen species (ROS) under certain pathological conditions. Because mtDNA in the mitochondrial matrix is exposed to ROS that leak from the respiratory chain, this extranuclear genome is prone to mutations. Therefore, the mitochondrial genome is a rich site for both deletions and mutations. The location and extent of mitochondrial DNA deletions and their relationships with mitochondrial localization, function (metabolism) and ES cell quality need to be addressed.
Accumulation of mtDNA mutations in the mi-tochondrial genome may be inherent in ES cells, especially those derived from IVP embryos, and this could contribute to impaired metabolism and thus to loss of functional competence. Several mutations of mitochondrial DNA occur in humans either as sporadic large-scale rearrangements (deletions and duplications) or maternally inherited point mutations, which have been associated with defined clinical syndromes. These include MERF and MELAS (McKenzie et al., 2004) . A particular mtDNA mutation called the "common deletion," ⌬mtDNA4977, has been detected in human oocytes at a frequency of 30-50% (Chen et al., 1995; Keefe et al., 1995; Brenner et al., 1998; Barritt et al., 1999) . Mitochondrial DNA mutations could result in diminished ATP content, leading to defects such as slow or arrested cell division, apoptosis, numerical chromosomal abnormalities such as aneuploidy, non-disjunction anomalies as illustrated by the monkey "in vitro" ES cell line with a translocation (Table 1) , and ultimately failure to differentiate (Barnett et al., 1997; van Blerkom et al., 1995 van Blerkom et al., , 2001 or uncontrolled loss of the undifferentiated state. However, adverse effects of mtDNA mutations associated with respiratory function would depend upon the magnitude of the mutant population (mutant load). This load could increase with each cell division and passage, and may be exacerbated by suboptimal culture conditions, especially use of supra-physiological oxygen concentrations that produce ROS. Functional defects could also result from asymmetrical mitochondrial distribution following cell division, which could lead to disproportionate mitochondrial inheritance, perhaps thereby producing cells with diminished ATP-generating capacity (van Blerkom et al., 1995 (van Blerkom et al., , 2000 .
In summary, mtDNA deletions are likely to occur in cultured ES cells and could affect their functional competence. Because of this, mitochondrial copy number and the frequencies of mtDNA deletions and mutations could be useful as markers of ES cell competence and viability.
MOLECULAR GENETIC ANALYSIS OF PRIMATE EMBRYONIC STEM CELLS
The functional efficacy of tissues and organs derived from ES cells is obviously a key issue. However, safety is also critical for ES cell-based therapies. Genetic abnormalities in ES cell lines used for replacement therapies could lead to cancerous tumor formation. The likelihood of being able to transplant pluripotent ES cells as a therapeutic approach is low until both of these issues are resolved. Therefore, we need to understand the genetic control of stem cell self-renewal to ensure that the lines maintain chromosome stability and are free of genetic mutations.
It is essential first to establish which genes are uniquely expressed in ES cells, that is, those representing "stemness," defined as a pattern of expression of genes that are common to all stem cell lines (Pyle et al., 2004; Pau and Wolf, 2004) . Currently, efforts to identify these genes have begun, but there is not yet a consensus, possibly because the different ES cell lines under investigation vary in their stemness properties. Global gene analysis of human ES cells has identified genes important for stem cell function that are common to all ES cells. Examples of such candidate genes are Nanog, Stat3, Sox2, Foxd 3 , Lefty A and Lefty B (Sato et al., 2003) . As we have emphasized above, it will be difficult to elucidate the normal regulation of stemness in ES cell lines without input from "in vivo"-derived cell lines that are known to be normal. Because such cell lines are not available in humans, it is important to establish molecular signatures of non-human primate ES cells as the transitional animal model for understanding the profile of stemness (Sato et al., 2003) . The next logical step will be efforts to use proteomics to identify specific proteins produced by stem cells.
CONCLUSION
The production of human ES cells involves destruction of human embryos, which some equate to the destruction of human life. Because of this, ES cell technology has become a volatile issue in the United States and in some other countries that has polarized public and legislative opinions and thereby restricted scientific progress. It is unfortunate that the intense controversy over human ES cells has obscured several important facts, including the following:
• Some human ES cell lines could be defective because of their source (IVP, cryopreserved embryos). • In humans, there is no "in vivo" standard for obtaining normal comparative data on ES cell characteristics, but there is in rhesus monkeys.
• Use of mouse feeder cells and serum-containing culture media can alter the characteristics of the NIH-approved human ES cell lines, and of the presently available non-human primate ES cells, during culture and differentiation, and this makes their use for therapeutic transplantation studies questionable, even if they are weaned off mouse feeder cells and serum.
• For therapeutic purposes, human oocytes will be needed to convert patients' somatic cells into ES cells via SCNT but there will not be enough high-quality oocytes available to meet the anticipated demand.
In addition to studies with human ES cell lines, using rhesus monkey ES cells will accelerate research and will produce data and technologies that can be extrapolated to humans. In both species, new ES cell lines are urgently needed that have not been exposed to mouse feeder cells or to serumcontaining culture media. However, the creation of new human ES cell lines will raise vigorous objections in the United States, which can be avoided by using non-human primate embryos instead. There is a critical need to increase understanding about the basic biology of ES cells, to couple genetic and functional assessments, and to identify markers of stemness and normality.
A paramount objective is to develop culture technologies for transforming somatic cells from a patient into ES cells that can be directed into forming functional replacement cells, tissues and organs, thus avoiding rejection problems and hence the need to take immunosuppressive drugs. This would also avoid any need for human oocytes to perform this transformation, thereby eliminating most ethical and logistical drawbacks to the use of human ES cell technology. We believe that using non-human primates as a transitional model could accelerate accomplishment of this goal.
